The first report on detecting SARS-CoV-2 inside human fecal-oral bacteria: A case series on asymptomatic family members and a child with COVID-19 [version 1; peer review: awaiting peer review]

Carlo Brogna1, Simone Cristoni2, Mauro Petrillo3,4, Domenico Rocco Bisaccia1, Francesco Lauritano1, Luigi Montano5, Marina Prisco6, Marina Piscopo6

1Department of Microbiology, Craniomed group facility Srl, Montemiletto, Avellino, 83038, Italy
2ISB Srl. Ion source & Biotechnologies Srl, Bresso, Milano, 20091, Italy
3Seidor Italy Srl, Milano, 20129, Italy
4European Commission, Joint Research Centre (JRC), Ispra, Italy
5Andrology Unit and Service of LifeStyle Medicine in Uro-Andrology, Local Health Authority, Salerno, 84124, Italy
6Department of Biology, University of Naples Federico II, Napoli, 80126, Italy

Abstract
Many studies report the importance of using feces as source sample for detecting SARS-CoV-2 in patients with COVID-19 symptoms but who are negative to oropharyngeal/nasopharyngeal tests. Here, we report the case of an asymptomatic child whose family members had negative results with the rapid antigen nasopharyngeal swab tests. The 21-month-old child presented with fever, diarrhea, bilateral conjunctivitis, and conspicuous lacrimation. In this study, analysis for the presence of SARS-CoV-2 in fecal samples by using Luminex technology allowed accurate detection of the presence of the viral RNA in the feces of the child and of all her relatives, which thus resulted to be positive but asymptomatic. It is the first time that SARS-CoV-2 is observed inside human fecal-oral bacteria and outside a matrix resembling extracellular bacterial lysates, in agreement with a bacteriophage mechanism with the images obtained by transmission electron microscopy (TEM), post-embedding immunogold, and by fluorescence microscope. In addition to the typical observations of respiratory symptoms, accurate evaluation of clinical gastrointestinal and neurological symptoms, combined with efficient highly sensitive molecular testing on feces, represent an efficient approach for detecting SARS-CoV-2, and for providing the correct therapy in challenging COVID-19 cases, like the one here reported.
Keywords
SARS-CoV-2, gut microbiota, bacteriophage, feces, diarrhea, nasopharyngeal swab, fecal oral transmission, TEM image, case series

This article is included in the Emerging Diseases and Outbreaks gateway.

Corresponding author: Carlo Brogna (dir.brogna@craniomed.it)

Author roles: Brogna C: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Cristoni S: Data Curation, Investigation, Software, Validation; Petrillo M: Formal Analysis, Investigation, Methodology, Software, Writing – Original Draft Preparation; Bisaccia DR: Data Curation, Investigation, Validation, Visualization; Lauritano F: Formal Analysis, Validation, Writing – Original Draft Preparation; Montano L: Validation, Visualization; Prisco M: Data Curation, Formal Analysis, Methodology, Validation, Writing – Original Draft Preparation; Piscopo M: Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: Author Carlo Brogna, Domenico Rocco Bisaccia, and Francesco Lauritano are employed by Craniomed Group. Author Mauro Petrillo is employed by Seidor Italy Srl. Author Simone Cristoni is employed by ISB Srl. All authors of the manuscript declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2022 Brogna C et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Brogna C, Cristoni S, Petrillo M et al. The first report on detecting SARS-CoV-2 inside human fecal-oral bacteria: A case series on asymptomatic family members and a child with COVID-19 [version 1; peer review: awaiting peer review] F1000Research 2022, 11:135 https://doi.org/10.12688/f1000research.77421.1

First published: 02 Feb 2022, 11:135 https://doi.org/10.12688/f1000research.77421.1
**Introduction**

In the past two years, humanity has been combating the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a positive, single-stranded RNA virus of the *Coronaviridae* family, specifically of the subfamily *Orthocoronavirinae* (usually called “coronaviruses”). Its closest known relatives are those found in bat feces, like the coronavirus RaTG13.1 Xu et al. (2020) studied viral behavior in 10 children, ranging in age from two months to 15 years. Although all of them were positive to the initial nasopharyngeal test, for eight of them, the viral charge was also positive in the stool. Moreover, they continued to test positive in the stool even after the negative nasal swab for several days after hospital discharge. In another Chinese study, the researchers found viral positivity in the fecal samples of 205 patients.4 Many studies have observed that fecal-oral transmission of the virus is possible and that it is very common to detect this virus in feces. Nevertheless, in comparison to the closest SARS-like viruses, SARS-CoV-2 appears to diverge in the receptor-binding domain of the spike glycoprotein, which is considered a key player in the entrance of the virus in human eukaryotic cells throughout its interaction with the angiotensin-converting enzyme 2 receptor (ACE-2), which in turn is considered the entry point of the virus.6 ACE-2 receptors and host cell transmembrane serine protease 2 (TMPRSS2) are abundant throughout the intestinal tract7 and several studies have reported altered intestinal bacterial flora or intestinal bacterial co-infection in COVID-19 patients. In terms of hosts, *coronaviridae* members are neither human-specific nor new in terms of discovery and treatments: a recent review describes the numerous zoonoses caused by the *Coronaviridae* family members,8 and scientists searched for the pathogen in the stool,9 a method that was, and continues to be, very common in the veterinary field. Among the coronaviruses previously found and analyzed in feces, there are those responsible for animal diseases like the calves’ enzootic pneumonia (caused by Bovine coronavirus, BCoV), or the porcine epidemic diarrhea (caused by the Porcine Epidemic Diarrhea Virus, PEDV). These diseases and other coronavirus-related ones very often show as initial clinical manifestation of violent diarrhea, and the affected animals have a significant alteration of the intestinal mucosa.9,11,12 Observations of possible links between the animal gut microbial environment and coronaviruses have been reported over time, supported also by the use of transmission electron microscopy (TEM) image analysis which screens and looks for viruses-like particles.8,13 The observation of SARS-CoV-2 particles by TEM can complement the molecular traces of it.14 Finally, it is worth noting that almost all of the latest characterized SARS-like viruses have been found and sequenced in bat fecal samples.15

Here, we report the case of a symptomatic child whose family members had negative results with rapid antigen nasopharyngeal swab test. Analyses of fecal samples detect the viral RNA presence in the feces of the child and of all her relatives, which thus resulted to be positive asymptomatic. Microscope image analyses confirm the presence of SARS-CoV-2-like particles on fecal samples of the family and suggest that bacteria, reservoirs of the virus, are the most critical factors of fecal-oral transmission in this pandemic. The present case report also emphasizes the importance of the rapid detection of SARS-CoV-2 in symptomatic and non-symptomatic subjects with negative results from nasal and oropharyngeal swabs by analyzing stool samples, and emphasizes the importance of the bacteriophagic mechanism of the virus and its fecal-oral transmission.

**Case series description**

A 21-month-old female, Caucasian child, presented to us with severe bilateral conjunctivitis, conspicuous lacrimation, diarrhea, malodorous stools, restlessness, and fever (38°C). The child’s medical history was negative for any disease. Parents reported that about a year earlier, she had a period when she had a severe cold. They were alarmed by violent diarrhea, which was preceded by 24 hours of constipation, as well as by the abnormal bilateral conjunctivitis with uncontrollable lacrimation. Rapid blood tests showed the following values (in bold are those out of normal range, NR): creatinine 0.18 mg/dL (NR: 0.40-1.10 mg/dL); glucose 97 mg/dL (NR: 60-110 mg/dL); aspartate transaminase 45 I.U. (NR: 10-50 I.U.); alanine transaminase 28 I.U. (NR: 10-35 I.U.); sodium 139 mEq/L (NR: 136-150 mEq/L); potassium 5.82 mEq/L (NR: 3.50-5.10 mEq/L); chloride 95 mEq/L (NR: 98-107 mEq/L); calcium 5.50 mEq/L (NR: 4.25-5.25 mEq/L); C-reactive protein 2.60 mg/L (NR: 0-5 mg/L); iron 28 mcg/dL (NR: 59-158 mcg/dL). Other complete blood count values were in the normal range.

The Caucasian family (six adults, three children) came to us, in the autumn of 2020, during one of the Italian regional lockdown periods. Some specific information on the family members were recorded, including age, sex, medical history, occupations, and relationships (see Table 1). They live in close proximity, divided among three apartments in one building (Figure 1 panel A). The parents reported that the children never had a babysitter since this task was entrusted to their grandparents, who were in their building. Moreover, they reported that since the outbreak of the pandemic (March 2020), they had adopted a series of measures, probably excessive in their opinion, with the purpose of protecting the grandparents and children from sickness. Such measures included no contact with people outside the family context, disinfection of every product purchased, no summer holidays, no eating at restaurants or other public places, and limited outings for the four parents (am1, af1, am3, af3) for work reasons only. The grandfather (am2), grandmother (af2), and the three children (cf1, 2cf1, cm3) did not leave the building for the duration of the lockdown (Figure 1A and Table 1). All the
### Table 1. Information about family members.

| Subject | Symptoms of COVID-19 | Stools Luminex AU Test before therapy (Initial) | Stools Luminex AU Test 60 days after therapy (Final) | Medical history or comorbidities | Age | Degree of the kinship with the child (cf1) affected by Covid-19 | Occupation |
|---------|----------------------|-----------------------------------------------|---------------------------------------------------|----------------------------------|-----|-------------------------------------------------------------|------------|
| am1     | No                   | 24                                            | 16                                                | Hepatic Steatosis               | 43  | Father                                                      | Worker in the health care sub-area |
| af1     | No                   | 23                                            | 0                                                 | Congenital heart disease: patent foramen ovale (PFO) and atrial septal aneurysm (ASA) | 38  | Mother                                                      | Worker in the health care sub-area |
| cf1     | Yes: bilateral conjunctivitis, conspicuous lacrimation, diarrhea, restlessness, and fever (38°C) | 33                                            | 0                                                 | Healthy                          | 21 months | The child affected by COVID-19                             | ---- |
| 2cf1    | No                   | 20                                            | 0                                                 | Healthy                          | 8   | Sister                                                      | Primary school student-lessons in “didactics distance” (DAD) for the lookdown period. |
| am2     | No                   | 20                                            | 0                                                 | Benign prostatic hyperplasia (BPH) | 69  | Maternal grandfather                                       | Retired- full-time grandfather with grandson cf1, cf2 and cm3 |
| af2     | No                   | 13                                            | 0                                                 | Diverticulosis; arterial hypertension | 67  | Maternal grandmother                                       | Retired- full-time grandfather with grandson cf1, cf2 and cm3 |
| am3     | No                   | 19                                            | 0                                                 | Healthy                          | 42  | Uncle                                                       | Worker in the health care sub-area |
| af3     | No                   | 12                                            | 0                                                 | Healthy                          | 39  | Maternal aunt                                               | ---- |
| am3     | No                   | 20                                            | 0                                                 | Healthy                          | 2   | Cousin                                                      | ---- |

Am1: adult male family 1; af1: adult female family 1; cf1: child female family 1; 2cf1: 2nd child female family 1; am2: grandfather family 2; af2: grandmother family 2; am3: adult male family 3; af3: adult female family 3; cm3: child male family 3. AU, arbitrary unit.
Figure 1. Case presentation and viral load. (A) Distribution of the nine people analyzed in the family. Red (cf1: child female family 1) shows the child who was symptomatic and had positive results on the fecal molecular test. Yellow: the other family 1,2,3 members (Am1: adult male family 1; af1: adult female family 1; 2cf1: 2nd child female family 1; am2: grandfather family 2; af2: grandmother family 2; am3: adult male family 3; af3: adult female family 3; cm3: child male family 3) who had positive results on the Luminex molecular fecal test but negative results on the rapid antigen nasopharyngeal swab test. (B) Positive control of fecal bacteria, at 30 days, with Luminex molecular test (AU)- (Petrillo et.al 2021) which confirmed the presence of SARS-CoV-2 (520 AU) after 30 days of bacterial culture. (B) Positive control of fecal bacteria, at 30 days, with Luminex molecular test (arbitrary unit, AU) which confirmed the presence of SARS-CoV-2 (520 AU) after 30 days of bacterial culture. (C-D) Viral load (Luminex bead count- AU) initially and after 60 days. The family members hired supplemental therapy with colloidal copper and bromelain, as well as with probiotics therapy with Lactobacillus reuteri and Bacillus clausii.
parents (am1, af1, am3, af3) of the children working in the health care sub-area left home daily to work, and one of them worked in another geographical region. Considering their work position it is most likely that the family infection started with the contagiousness of one of the four parents (am1, af1, am3, af3) who were asymptomatic during working hours. Of interests is the medical history of one adult (am1), the father of child cf1 (our COVID-19 patient), that was hospitalized precisely one year prior (autumn 2019) with escalating symptoms of violent diarrhea, abdominal pain, fever (38°C), dyspnea, cough, headache, shortness of breath, and fainting. There was saturation of 91% SpO2%, right bundle branch block, increased D-Dimer, increased liver values (GOT and GPT), and mild lymphopenia, treated with antibiotics.

We initially performed rapid antigen nasopharyngeal swab test (COVID-19 Ag Rapid Test Device, Abbott 41FK10) on the child (cf1), and it was negative. The same test was also performed on the parents (am1, af1) and the other six family members, and all results were negative. We had, in line with previous studies, experience of multiple negative results SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction (RT-PCR) tests on oropharyngeal/nasopharyngeal (OP/NP) swab samples from individuals with a strong clinical suspicion of COVID-19. Being in the presence of a very young patient, it was decided to adopt a fast high-throughput COVID-19 screening approach to detect the presence of SARS-CoV-2 directly from stool samples: in the following 24 hours, stool samples were collected from all nine family members, and molecular testing for SARS-CoV-2 was performed by using Luminex technology as described by us previously. Negative and positive controls as bacterial cell cultures of stool samples were those used and described in this previous study.

A summary of the analyses is reported in Figure 1C-D and Table 1: all family members had positive results to the Luminex molecular test, and the child with symptoms (cf1) showed the highest value of the Luminex assay. The other family members did not manifest any symptoms, despite being positive for the presence of viral RNA in their stools.

The child was treated for 48 hours only with rehydration and probiotics only; because of the absence of significant symptoms such as cough or dyspnea, no cortisone or antibiotics were administered. Conjunctivitis and lacrimation ceased about 72 hours later and the patient was discharged. The entire family, including the reported patient, were then instructed to take probiotics (Lactobacillus reuteri, 100 million units, one time per day, and Bacillus clausii 2 billion units, per day) in addition to bromelain, 300 mgr. per day, and colloidal copper, 20 ppm (parts per million) per day for 30 days. After 60 days, both the rapid antigen nasopharyngeal swab test (COVID-19 Ag Rapid Test Device, Abbot 41FK10) and the Luminex test were repeated: all family members were negative to the rapid antigen tests, and only one family member (Figure 1D-am1) continued to have Luminex positive results. Patient am1, male, Caucasian and a healthcare employee, continued the treatment until he became negative at day 90 for the presence of SARS-CoV-2 in stools. Bacterial feces of this patient, after 30 days of bacterial culture, have been analyzed by TEM, immune-EM, and by fluorescence microscopy, and a set of obtained images is shown in Figure 2. At day 30 of bacterial culture of feces patient am1, the Luminex molecular test confirmed the presence of SARS-CoV-2 and the RNA viral load count was increased from 24 arbitrary unit (AU) (initial) to 520 AU (Final) (Figure 1B) in accordance with our previous observations.

Transmission electron microscope images (panels A and B of Figure 2-Tecnai G2 Spirit BioTwin; FEI, equipped with a VELETTA CCD digital camera -Soft Imaging Systems GmbH) SARS-CoV-2 (black arrows) inside a bacterium (A) and outside a matrix resembling extracellular lysate of a bacterium (B). No eukaryotic cells have been ever observed after 30 days of bacterial culture. Post-embedding immunogold (Figure 2 Panel C, D): bacteria pellets were fixed with a mixture of 0.05% glutaraldehyde of 4% paraformaldehyde in 0.1M PBS (Phosphate-buffered saline) buffer, washed in PBS buffer, pelleted at 10000g and included in 3% agarose. The agarose block was cut into tissue-size pieces and the slices were post-fixed in 2% OsO4, dehydrated in a series of ethanol solutions of increasing concentration and in propylene oxide and finally embedded in Epon 812. Thin sections were cut from embedded specimens using Reichert Jung Ultra microtome and are applied to Formvar/Carbon Supported nickel grids. Sections were blocked with normal goat serum for 1h at room temperature, incubated with rabbit monoclonal to SARS-CoV-2 nucleocapsid protein antibody (EPR24334-118, Abcam) and then with secondary anti-rabbit antibody 10nm gold-conjugated (Aurion). Electron microscopy images were acquired from thin sections under an electron microscope (Tecnai G2 Spirit BioTwin; FEI) equipped with a VELETTA CCD digital camera (Soft Imaging Systems GmbH).

The immunofluorescence microscope (Figure 3, panels A; B, C, D - Zeiss Axioplan 2, Axiocam 305 color, magnification 100×) was performed in accordance to manufacturers’ protocol using as primary antibodies versus SARS-CoV-2 Nucleocapsid protein ("Sars Nucleocapsid Protein Antibody [Rabbit Polyconal] - 500 μg 200-401-A50 Rockland", and the "Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Cyanine3™ #A10520" as secondary antibody). It was used also a primary antibody versus gram-positive bacteria ("Gram-Positive Bacteria Ab (BDI380), GTX42630 Gene Tex") and "Goat anti-Mouse IgG (H+L), Super-clonal™ Recombinant Secondary Antibody, Alexa Fluor 488" as secondary antibody. The images confirm the presence of SARS-CoV-2 particles (red light in the fluorescence images) in relationship with the bacteria (green light in the fluorescence images).
To our knowledge, this is the first time that a member of coronaviruses’ family, the SARS-CoV-2, has been observed inside human fecal-oral bacteria (Figure 2 panel A–C) and outside a matrix resembling extracellular lysates (Figure 2, panel B), in agreement with a phage-like behavior reported by us.21

Discussion
Zheng F. et al.24,25 observed that gastrointestinal symptoms are common in children with SARS-CoV-2 and are associated with fever, nausea, vomiting, and abdominal pain. However, their case series is probably not very large both because it is known that more than half of sick children have mild to moderate symptoms and because hospitalizations are not as common as for other respiratory viruses.24 A recent example of the fecal-oral transmission is well described in a short communication by Hansen et al.26 These authors reported the case of an 86-year-old man who, despite of having been vaccinated (first dose of BNT162b2 mRNA COVID-19 vaccine), eighteen days after vaccination was admitted to the hospital for diarrhea, with no other symptoms of COVID-19, and had negative results on antigen and PCR testing until

Figure 2. Transmission electron microscopy (post-embedded immunogold). Images were obtained at day 30 of bacterial culture of patient’s feces, in which a molecular test with Luminex confirmed the presence of SARS-CoV-2 and an increase of RNA viral load from initial 24 arbitrary unit (AU) to 520 AU final. (A-B) Transmission electron microscope images (panels A and B - TEM FEI Tecnai G2 operating at 120 kV) show SARS-CoV-2 (indicated by black arrows) inside a bacterium (A) and outside a matrix resembling extracellular lysate of a bacterium (B). (C-D) Post-embedding immunogold: rabbit monoclonal to SARS-CoV-2 Nucleocapsid protein antibodies ligating to the secondary anti-rabbit antibody 10nm gold-conjugated indicated the virus inside bacteria of gut microbiota (Tecnai G2 Spirit BioTwin; FEI equipped with a VELETTA CCD digital camera (Soft Imaging Systems GmbH)).

Figure 3. Transmission electron microscopy (post-embedded immunogold). Images were obtained at day 30 of bacterial culture of patient’s feces, in which a molecular test with Luminex confirmed the presence of SARS-CoV-2 and an increase of RNA viral load from initial 24 arbitrary unit (AU) to 520 AU final. (A-B) Transmission electron microscope images (panels A and B - TEM FEI Tecnai G2 operating at 120 kV) show SARS-CoV-2 (indicated by black arrows) inside a bacterium (A) and outside a matrix resembling extracellular lysate of a bacterium (B). (C-D) Post-embedding immunogold: rabbit monoclonal to SARS-CoV-2 Nucleocapsid protein antibodies ligating to the secondary anti-rabbit antibody 10nm gold-conjugated indicated the virus inside bacteria of gut microbiota (Tecnai G2 Spirit BioTwin; FEI equipped with a VELETTA CCD digital camera (Soft Imaging Systems GmbH)).
day 26, when he died of acute renal and respiratory failure. On day 24, the older man’s roommate tested positive for SARS-CoV-2 RT-PCR on a nasal swab. Autopsy results of the 86-year-old decedent indicated the presence of the virus in the organs examined except for the liver and olfactory bulb.

In one of the first studies on SARS-CoV-2 in Wuhan, prominent symptoms of COVID-19 patients are described, including diarrhea and in children, gastrointestinal disorders are the most prevalent. The persistence of coronaviruses in feces, for a long time, had already been observed many years ago. In one of the first case reports of 1982, Baker et al. described the case of a 47-year-old Indian man who underwent surgery for a duodenal ulcer when he was 13 years old. The symptoms that forced hospitalization were diarrhea and steatorrhea. The man was monitored for eight months, and in 17 fecal samples, coronavirus-like particles were observed by electron microscopy. The images show two ovoid/geoid shaped coronavirus particles with the spike protein evident and one circular shaped coronavirus particle but without surface proteins, like those here reported in Figure 2.

Figure 3. Fluorescence microscope images. Panels A, B, C, D (Zeiss Axioplan 2, Axiocam 305 color, magnification 100×) show immunofluorescence staining versus SARS-CoV-2 nucleocapsid protein (red light), gram positive bacteria (green light). Panel E is the negative control. The roman numerals I,II,III,IV and yellow rectangles indicate four gram-positive bacteria (green light) infected by SARS-CoV-2 (red light).
Inclusion of symptoms other than respiratory, such as gastrointestinal symptoms, seems to be very important in the diagnostic process. Although diarrhea and conjunctivitis with lacrimation, as in our case, may be unlinked, they can be related to each other if the gut microbiota and the central, peripheral, and autonomous nervous systems are taken into account. The gut microbiota seems to be extremely important and interconnected with the central, peripheral, autonomic, neuroimmune, and neuroendocrine nervous system axis. An altered gut microbiota or the total absence of bacteria, as in germ-free mice, can affect areas of the brain, including the hippocampus, the point of end of olfactory system. Several studies have reported an impairment of intestinal gut microbiota or respiratory and intestinal bacterial coinfection in COVID-19.

As shown in Figures 2-3, bacteria could play crucial role in the possibility of fecal-oral transmission. This news isn’t so far away from the most recent studies in which we described that RNA replication of the SARS-CoV-2 virus can take place in bacterial cultures. We also described that the use of certain drugs can decrease its replication in vitro. Moreover, in the same work, we observed, by mass spectrometry, the mutational phenomenon of viral proteins in bacterial cultures. Other authors have also noted the possibility that the spike protein of the SARS-CoV-2 may interact with the lipopolysaccharide of Escherichia coli or that the absence of proteobacteria could play a key role in the pathogenesis of respiratory viral diseases. This is why early localization in the stool assumes considerable importance. Since the discovery of SARS-CoV-2, a plethora of commercial tests have become available, and, currently, more than 1,700 tests are commercialized in the European Union countries (source JRC COVID-19 In Vitro Diagnostic Devices and Test Methods Database). Rapid Antigen Tests (RATs) are recommended to be routinely used, especially on oropharyngeal/nasopharyngeal (OP/NP) swab samples. Researchers have had sometimes problems in terms of sensitivity and specificity with some of them. Problems may arise because the tests were initially evaluated on samples from patients with severe COVID-19, who are suggested to develop a much higher immune response than those with mild or asymptomatic disease.

RT-PCR is considered the gold standard method for detection of SARS-CoV-2. However, we had previous experience of multiple negative results SARS-CoV-2 RT-PCR tests on OP/NP swab samples from individuals with a strong clinical suspicion of COVID-19. Mardian et al. 2021 recommend fecal detection of viral RNA when nasopharyngeal swab data are questionable. In addition, the RNA virus could be present in the 48.1% of patients who were negative to OP/NP swab tests until 33 days. Finally, in a recent study aimed to evaluate the role of fecal-oral transmission, unique RNA SARS-CoV-2 genomic sequence mutations have been observed by performing next-generation sequencing on the fecal samples. In this case the Luminex technology as molecular testing tool was chosen because it is ideal for fast high-throughput COVID-19 screening and its clinical performance have been evaluated.

In consideration that SARS-CoV-2 was detected at low levels in fecal samples, in addition to molecular test, was agreed to verify the presence of the virus by acquiring images of at least one sample. As proposed by Dittmayer and colleagues, in the case of COVID-19 diagnosis, the use of image analysis to confirm the presence of SARS-CoV-2 particles complements detection of molecular traces of SARS-CoV-2 specific proteins or nucleic acids (and vice versa). In studies of infectious diseases, TEM is used very often to definitively prove the presence of an infectious unit. The images were obtained by TEM, immune-EM, and by fluorescence microscope. What we have noted is (in agreement with our first observations), there is a crucial role of bacteria in the fecal-oral transmission of SARS-CoV-2. The only limitations of such investigations are the high costs and long waiting times.

Conclusions
Here, we report the case of a symptomatic child for COVID 19, brought to her by one of the parents, whose family members had negative results with rapid antigen nasopharyngeal swab test. Analyses of fecal samples by high-throughput COVID-19 screening (Luminex technology) allowed us to accurately detect the viral RNA presence in the faces of the child and of all her relatives, which thus resulted to be positive asymptomatic.

Microscopy images analysis was used as complementary approach to confirm the presence of SARS-CoV-2 in bacterial cultures obtained by fecal sample of an infected individual with the viral RNA load positive individual. The images obtained by TEM, immune-EM and by fluorescence microscope show SARS-CoV-2 inside human gut bacteria and outside a matrix resembling extracellular bacterial lysates, in agreement with a bacteriophage mechanism. This surprising finding allows us to better clarify the first fecal-oral transmission of the virus and clearly shows that the reservoir of the virus is neither adults nor children but simply bacteria.

We believe that accurate analysis of the human gut microbiome during viral infections, including SARS-CoV-2 infections, may be of great importance and may aid in diagnosis when other tests fail. According to the other studies, faster and more versatile tests should be improved to decrease or cope with the contagiousness of the pathogens, especially to detect them in the stools. The observation of all clinical symptoms, typically respiratory, gastrointestinal,
and neurological, combined with molecular testing (stool, sputum, tear, other fluids) and image analysis, represents the key for understanding the interaction of SARS-CoV-2 with the human microbiome. Therefore, for the provision of the correct epidemiology, diagnosis and accurate therapeutic approach is important in the treatment of COVID-19, especially in challenging cases, such as the one reported here. This case also highlights the possibility of contagion from asymptomatic parents to their children.

Data availability
All data underlying the results are available as part of the article and no additional source data are required.

Consent
Written informed consent for publication of their clinical details and clinical images was obtained from the parents of the child. Written informed consent for publication of their clinical details and clinical images was also obtained from all other patients involved in the study.

Acknowledgments
We thank Tigem Institute-Telethon Pozzuoli Naples for the microscope electron images preparations. We thank Biogem Institute of Ariano Irpino (Av), for fluorescence microscope images preparations. We also are grateful to Electron microscopy facility of the department of chemical sciences- University of Study Federico II Naples (UniNa). We are also grateful to Marsan consulting and Dr Marino Giuliano for their full support. We thank the entire family and all the patients for allowing this work. This paper is a new gift for all the children of the world.

References

1. Zhang L, Shen FM, Chen F, et al.: Origin and Evolution of the 2019 Novel Coronavirus. Clin. Infect. Dis. 2020 Jul 28; 71(15): 882-883. PubMed Abstract | Publisher Full Text | Free Full Text
2. Xu Y, Li X, Zhu B, et al.: Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat. Med. 2020; 26(4): 502-505. PubMed Abstract | Publisher Full Text
3. Guo M, Tao W, Flavel RA, et al.: Potential intestinal infection and faecal-oral transmission of SARS-CoV-2. Nat. Rev. Gastroenterol. Hepatol. 2021; 18(4): 269-283. PubMed Abstract | Publisher Full Text | Free Full Text
4. Wang W, Xu Y, Gao R, et al.: Potential intestinal infection and faecal-oral transmission of SARS-CoV-2. Nat. Rev. Gastroenterol. Hepatol. 2021; 18(4): 269-283. PubMed Abstract | Publisher Full Text | Free Full Text
5. Lindman E, Einarsson J, Larsson S, et al.: SARS-CoV-2 infection in the digestive system. Gut 2020; 69(6): 1010-1018. PubMed Abstract | Publisher Full Text
6. Hoffmann M, Kleine-Weber H, Schroeder S, et al.: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16; 181(2): 271-280.e8. PubMed Abstract | Publisher Full Text | Free Full Text
7. Sajdel-Sulkowska EM: A Dual-Route Perspective of SARS-CoV-2 Infection: Lung vs. Gut-specific Effects of ACE2-Deficiency. Front. Pharmacol. 2021 Jun 11; 12: 684610. PubMed Abstract | Publisher Full Text | Free Full Text
8. Zhang H, Kang Z, Gong H, et al.: Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. Gut. 2020; 69(6): 1010-1018. PubMed Abstract | Publisher Full Text
9. Alluwariri AM, Alshubaith IH, Al-Ali AM, Abohelaika S: The Coronavirus of Animals and Birds: Their Zoonosis, Vaccines, and Models for SARS-CoV and SARS-CoV-2. Front Vet Sci. 2020; 7: 582287. PubMed Abstract | Publisher Full Text
10. Rosenbaum MJ, Kory RC, Siegesmund KA, et al.: Electron microscope methods for the identification of adenoviruses isolated in micro tissue cultures. Appl. Microbiol. 1972 Jan; 23(1): 141-144. PubMed Abstract | Publisher Full Text | Free Full Text
11. Chen Q, Li G, Stasko J, et al.: Isolation and characterization of porcine epidemic diarrhea viruses associated with the 2013 disease outbreak among swine in the United States. J. Clin. Microbiol. 2014 Jan; 52(1): 234-243. PubMed Abstract | Publisher Full Text | Free Full Text
12. Scherer WP, Schwartz K, Burrough ER, et al.: The effect of porcine reproductive and respiratory syndrome virus and porcine epidemic diarrhea virus challenge on growing pigs I: Growth performance and digestibility. J. Anim. Sci. 2016 Feb; 94(2): 514-522. PubMed Abstract | Publisher Full Text | Free Full Text
13. Bhatnagar R, Johnson GR, Christian RG: Electron microscopy of rapid identification of animal viruses in hematolympho-ecin sections. Can. J. Comp. Med. 1977 Oct; 41(4): 416-419. PubMed Abstract | Free Full Text
14. Dittmayer C, Meinhardt J, Radbruch H, et al.: Misinterpretation of electron micrographs in SARS-CoV-2-infected tissue goes viral. Lancet. 2020; 396(10260): e64-e65. PubMed Abstract | Publisher Full Text
15. Ge XY, Li JL, Yang XL, et al.: Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013 Nov 28; 509(751): 535-538. PubMed Abstract | Publisher Full Text | Free Full Text
16. Cheung KS, Hung JF, Chan PPY, et al.: Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis. Gastroenterology. 2020 Jul; 159(1): 81-95. PubMed Abstract | Publisher Full Text | Free Full Text
17. Papoutsis A, Borody T, Dolai S, et al.: Detection of SARS-CoV-2 from patient fecal samples by whole genome sequencing. Gut Pathog. 2021 Jan 30; 13(1): 7. PubMed Abstract | Publisher Full Text | Free Full Text
18. Brogna B, Brogna C, Petrillo M, et al.: SARS-CoV-2 Detection in Fecal Samples from a Patient with Typical Findings of COVID-19 Pneumonia on CT but Negative to Multiple SARS-CoV-2 RT-PCR Tests on Oropharyngeal and Nasopharyngeal Swab Samples. Medicine (Kaunas). 2021 Mar 20; 57(3): 290. PubMed Abstract | Publisher Full Text | Free Full Text
19. Dunbar SA: Applications of Lumine xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin. Chim. Acta. 2006; 363(1-2): 71-82. PubMed Abstract | Publisher Full Text
20. Yip CC, Sridhar S, Cheng AK, et al.: Evaluation of the commercially available LightMix™ Modular E-gene kit using clinical and proficiency testing specimens for SARS-CoV-2 detection. J. Clin. Virol. 2020; 129: 104476. PubMed Abstract | Publisher Full Text
21. Petrillo M, Brogna C, Cristoni S, et al.: Increase of SARS-CoV-2 RNA load in faecal samples prompts for rethinking of SARS-CoV-2 biology and COVID-19 epidemiology. F1000Res. 2021 May 11; 10: 370. PubMed Abstract | Publisher Full Text | Free Full Text

22. de Vries M, Mohamed AS, Prescott RA, et al.: A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL\textsuperscript{pro} inhibitor PF-00835231 as a potential new treatment for COVID-19. J. Virol. 2021 Feb 23; 95(10): e01819-20. PubMed Abstract | Publisher Full Text | Free Full Text

23. Sasaki M, Uemura K, Sato A, et al.: SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells. PLoS Pathog. 2021 Jan 21; 17(1): e1009233. PubMed Abstract | Publisher Full Text | Free Full Text

24. Zheng F, Liu C, Fan QH, et al.: Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China. Curr. Med. Sci. 2020 Apr; 40(2): 275–280. PubMed Abstract | Publisher Full Text | Free Full Text

25. Kelvin AA, Halperin S: COVID-19 in children: the link in the transmission chain. Lancet Infect. Dis. 2020; 20(6): 633–634. Publisher Full Text

26. Hansen T, Titz U, Kulamadayil-Heidenreich NSA, et al.: First case of postmortem study in a patient vaccinated against SARS-CoV-2. Int. J. Infect. Dis. 2021 Jun; 107: 172–175. PubMed Abstract | Publisher Full Text | Free Full Text

27. Wang D, Hu B, Hu C, et al.: Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published correction appears in JAMA. 2020 Mar 16;323(11):1091]. JAMA. 2020; 323(11): 1061–1069. PubMed Abstract | Publisher Full Text

28. Baker SJ, Mathan M, Mathan VL, et al.: Chronic enterocyte infection with coronavirus. One possible cause of the syndrome of tropical sprue? Dig. Dis. Sci. 1982 Nov; 27(11): 1039–1043. PubMed Abstract | Publisher Full Text | Free Full Text

29. Dinan TG, Cryan JF: Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration. J. Physiol. 2017; 595(2): 489-503. PubMed Abstract | Publisher Full Text

30. Petrlik G, Puthia M, Petriova J, et al.: SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity. J. Mol. Cell Biol. 2020 Oct 12; 12(12): 916–932. PubMed Abstract | Publisher Full Text | Free Full Text

31. Cypryan F, Sohail MU, Abdelhafez I, et al.: SARS-CoV-2 and immune-microbiome interactions: Lessons from respiratory viral infections. Int. J. Infect. Dis. 2021; 105: 540–550. PubMed Abstract | Publisher Full Text

32. Langford BJ, Se M, Raybardhan S, et al.: Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin. Microbiol. Infect. 2020 Dec; 26(12): 1622–1629. PubMed Abstract | Publisher Full Text | Free Full Text

33. Honarmand EK: SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection. FEBS Lett. 2020 Jun; 594(11): 1651–1660. PubMed Abstract | Publisher Full Text | Free Full Text

34. Petrillo M, Querci M, Tkachenko O, et al.: The EU one-stop-shop collection of publicly available information on COVID-19 in vitro diagnostic medical devices. F1000Res. 2020 Nov 3; 9: 1296. PubMed Abstract | Publisher Full Text | Free Full Text

35. Council Recommendation on a common framework for the use and validation of rapid antigen tests and the mutual recognition of COVID-19 test results in the EU 2021/C 24/01. Reference Source

36. EU health preparedness: A common list of COVID-19 rapid antigen tests and a common standardised set of data to be included in COVID-19 test result certificates. Reference Source

37. Kramer F, Simon V: Serology assays to manage COVID-19. Science. 2020 Jun 5; 368(6495): 1060–1061. PubMed Abstract | Publisher Full Text

38. Xiao T, Wang Y, Yuan J, et al.: Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers. Front Med. (Lausanne). 2021 Mar 15; 8: 595773. PubMed Abstract | Publisher Full Text | Free Full Text

39. Mardian Y, Kosash H, Karyana M, et al.: Review of Current COVID-19 Diagnostics and Opportunities for Further Development. Front Med (Lausanne). 2021 May 7; 8: 615099. PubMed Abstract | Publisher Full Text | Free Full Text

40. Chen JH, Yip CC, Chan JF, et al.: Clinical Performance of the Luminex NxTag CoV Extended Panel for SARS-CoV-2 Detection in Nasopharyngeal Specimens from COVID-19 Patients in Hong Kong. J. Clin. Microbiol. 2020 Jul 23; 58(8): e00936-20. PubMed Abstract | Publisher Full Text | Free Full Text

41. Wang W, Xu Y, Gao R, et al.: Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020; 323(18): 1843–1844. PubMed Abstract | Publisher Full Text
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com